A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies

We conducted a single‐center, open‐label, dose escalation, and expansion phase I trial of the antiangiogenic multikinase inhibitor regorafenib in patients with advanced myeloid neoplasms. We enrolled 16 patients with relapsed/refractory acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN...

Descripción completa

Detalles Bibliográficos
Autores principales: How, Joan, Ren, Siyang, Lombardi‐Story, Jennifer, Bergeron, Meghan, Foster, Julia, Amrein, Phillip C., Brunner, Andrew M., Fathi, Amir T., Hock, Hanno, Khachatryan, Anna, Kikuchi, Hiroto, Ng, Mei Rosa, Moran, Jenna, Narayan, Rupa, Neuberg, Donna, Ramos, Aura, Som, Tina, Vartanian, Meghan, Chen, Yi‐Bin, Duda, Dan G., Hobbs, Gabriela S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Myeloid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175677/
https://www.ncbi.nlm.nih.gov/pubmed/35846042
http://dx.doi.org/10.1002/jha2.408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175677/
https://www.ncbi.nlm.nih.gov/pubmed/35846042
http://dx.doi.org/10.1002/jha2.408

Ejemplares similares